Study of FTY720 in Patients With Uveitis

Novartis

Status and phase: Withdrawn; Phase 2

Conditions: Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Treatments: Drug: FTY720; Drug: Oral Corticosteroid

Study type: Interventional

Funder types: Industry

Identifiers

NCT01791192

2011-004160-30 (EudraCT Number)

CFTY720D2205

Details and patient eligibility

About

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute noninfectious posterior, intermediate, or pan uveitis
• Vitreous haze score of 1+ or more in the study eye at screening and baseline visits

Exclusion criteria

• Vaso-occlusive vasculitis involving the retinal macula
• Behçet's uveitis
• Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted)
• Other protocol defined inclusions and/or exclusions may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

0 participants in 2 patient groups

FTY720

Experimental group

Description:

Fingolimod

Treatment:

Drug: FTY720

Oral Corticosteroid

Active Comparator group

Description:

Oral Corticosteroid

Treatment:

Drug: Oral Corticosteroid